[{"NetIncomeLoss_2_Q2_USD":889000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":7522000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":5533000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":43342000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":88122000.0,"AssetsCurrent_0_Q2_USD":455823000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":10697000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":1346703.0,"ProceedsFromSaleOfShortTermInvestments_2_Q2_USD":95450000.0,"Depreciation_1_Q2_USD":3000000.0,"Depreciation_2_Q2_USD":5900000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":7557000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":1490000.0,"PaymentsToAcquireShortTermInvestments_2_Q2_USD":72263000.0,"InterestPaidNet_2_Q2_USD":4097000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":33097000.0,"EquitySecuritiesFvNiUnrealizedGain_1_Q2_USD":4000000.0,"EquitySecuritiesFvNiUnrealizedGain_2_Q2_USD":100000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":47684000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":8202000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":11656000.0,"ConvertibleDebtNoncurrent_0_Q2_USD":314182000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":10423000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":179961000.0,"CommonStockSharesAuthorized_0_Q2_shares":250000000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":1701000.0,"PaymentsToAcquireBusinessesNetOfCashAcquired_2_Q2_USD":0.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":10980000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":30906000.0,"DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_1_Q2_USD":200000.0,"DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2_Q2_USD":100000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":22.05,"SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCarryingAmount_0_Q2_USD":10930000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_Q2_USD":41.93,"OperatingLeaseRightOfUseAsset_0_Q2_USD":77799000.0,"ShareBasedCompensation_1_Q2_USD":9222000.0,"ShareBasedCompensation_2_Q2_USD":18070000.0,"Assets_0_Q2_USD":866111000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":256501000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":9699000.0,"CommonStockSharesIssued_0_Q2_shares":42608257.0,"IncomeTaxesPaidNet_2_Q2_USD":80000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":75216000.0,"GainLossOnSaleOfPropertyPlantEquipment_2_Q2_USD":-22000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"NumberOfReportableSegments_2_Q2_segment":1.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-42000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":356000.0,"AccountsReceivableNetCurrent_0_Q2_USD":44013000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":3969000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-136000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-21468000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":42221000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":42861000.0,"EarningsPerShareBasic_1_Q2_USD":-0.17,"EarningsPerShareBasic_2_Q2_USD":0.02,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":9636000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":112414000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q2_USD":44.34,"ResearchAndDevelopmentExpense_1_Q2_USD":13620000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":29440000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":7497000.0,"ShortTermInvestments_0_Q2_USD":248240000.0,"DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_1_Q2_USD":-1418000.0,"CommonStockValue_0_Q2_USD":43000.0,"PaymentForContingentConsiderationLiabilityOperatingActivities_2_Q2_USD":9409000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2_Q2_USD":-5155000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1_Q2_USD":-666000.0,"OperatingLeaseLiability_0_Q2_USD":81508000.0,"EquityMethodInvestments_0_Q2_USD":10000000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":2536000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":1168000.0,"GainLossOnInvestments_2_Q2_USD":8000.0,"Liabilities_0_Q2_USD":477963000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":73888000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":78552000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":1967000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AmortizationOfIntangibleAssets_2_Q2_USD":3933000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-4733000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":2057000.0,"IncreaseDecreaseInInventories_2_Q2_USD":8394000.0,"CostsAndExpenses_1_Q2_USD":82652000.0,"CostsAndExpenses_2_Q2_USD":171242000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2_Q2_USD":-2312000.0,"PaymentForContingentConsiderationLiabilityFinancingActivities_2_Q2_USD":5591000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":2183000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":9810000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-3517000.0,"OperatingIncomeLoss_2_Q2_USD":9947000.0,"OperatingIncomeLoss_1_Q2_USD":-7147000.0,"AllowanceForDoubtfulAccountsReceivable_0_Q2_USD":0.0,"CostOfRevenue_2_Q2_USD":52037000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":42221000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":42126000.0,"RepaymentsOfDebt_2_Q2_USD":0.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":23894000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-9416000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":18070000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":9222000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_Q2_USD":61.24,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_Q2_shares":31982.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-7311000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":1245000.0,"Goodwill_0_Q2_USD":99547000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":1490000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":2536000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":1168000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":81217000.0,"PaymentsToAcquireEquityMethodInvestments_2_Q2_USD":0.0,"EarningsPerShareDiluted_1_Q2_USD":-0.17,"CostOfRevenue_1_Q2_USD":22305000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":10745000.0,"LiabilitiesCurrent_0_Q2_USD":70583000.0,"AccountsPayableCurrent_0_Q2_USD":9160000.0,"NetIncomeLoss_1_Q2_USD":-7269000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":113297000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"OperatingLeasePayments_1_Q2_USD":8503000.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":100454000.0,"InterestReceivable_0_Q2_USD":1700000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":1421000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2_Q2_USD":1421000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":427606.0,"EarningsPerShareDiluted_2_Q2_USD":0.02,"AdditionalPaidInCapital_0_Q2_USD":785124000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":100454000.0,"AssetRetirementObligation_0_Q2_USD":200000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":6353000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":18328000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":78552000.0,"InterestExpense_1_Q2_USD":5456000.0,"InterestExpense_2_Q2_USD":11477000.0,"NonoperatingIncomeExpense_1_Q2_USD":-164000.0,"NonoperatingIncomeExpense_2_Q2_USD":-8702000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0688,"CommonStockSharesOutstanding_0_Q2_shares":42608257.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-3517000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":324000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_Q2_shares":150954.0,"AmortizationOfDebtDiscountPremium_2_Q2_USD":7254000.0,"StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_Q2_USD":0.0,"StockIssuedDuringPeriodValueRestrictedStockAwardGross_1_Q2_USD":0.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":9222000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":18070000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":866111000.0,"OperatingLeaseCost_1_Q2_USD":2422000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":194514000.0,"OperatingLeaseCost_2_Q2_USD":3986000.0,"PreferredStockValue_0_Q2_USD":0.0,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":110090000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_Q2_USD":46.72,"RestrictedStockExpense_1_Q2_USD":2636000.0,"RestrictedStockExpense_2_Q2_USD":5037000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"InvestmentIncomeInterest_1_Q2_USD":1323000.0,"InvestmentIncomeInterest_2_Q2_USD":2911000.0,"InventoryNet_0_Q2_USD":66690000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_Q2_USD":27.26,"DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_2_Q2_USD":2290000.0,"SharePrice_0_Q2_USD":52.47,"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0_Q2_USD":3900000.0,"LeaseCost_1_Q2_USD":3023000.0,"LeaseCost_2_Q2_USD":5035000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-398509000.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2_Q2_pure":0.85,"VariableLeaseCost_1_Q2_USD":601000.0,"VariableLeaseCost_2_Q2_USD":1049000.0,"TaxesPayableCurrent_0_Q2_USD":1615000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":7442539.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q2_USD":75505000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":7620000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_2_Q2_USD":181189000.0,"LongTermInvestments_0_Q2_USD":8261000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1_Q2_USD":-6645000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2_Q2_USD":6400000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":255011000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q2_USD":0.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":15630000.0,"StockholdersEquity_0_Q2_USD":388148000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":2984000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q2_USD":42101000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":-3052000.0,"StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2_Q2_shares":36668.0,"Ticker":"PCRX","CIK":"1396814","name":"PACIRA BIOSCIENCES, INC.","OfficialName":"Pacira BioSciences Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"3316489486.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]